Table 2.
Main data on invasive mycosis.
| Group A | Group B | Total | |
| Type of mycosis | |||
| Probable | 13 | 7 | 20 |
| Documented | 9 | 11 | 20 |
| Severe neutropenia at diagnosis of IFI | 17 | 14 | 31 |
| Lymphocyte count at diagnosis of IFI | |||
| Median (× 109/L) | 100 | 200 | 170 |
| Range | (0–2230) | (0–5710) | (0–5710) |
| IS therapy at IFI | |||
| Steroids | 14 | 13 | 27 |
| CSA or FK 506 * | 8 | 6 | 14 |
| Number of organ involved | |||
| 1 | 17 | 12 | 29 |
| 2 | 3 | 4 | 7 |
| ≥ 3 | 2 | 2 | 4 |
| Type of organ involvement | |||
| Lung | 22 | 17 | 39 |
| CNS | 3 | 1 | 4 |
| Skin | 1 | 2 | 3 |
| URA | 2 | 0 | 2 |
| Heart | 0 | 2 | 2 |
| Other | 1 | 6 | 7 |
| Surgery | 7 | 7 | 14 |
| Site | |||
| Lung | 6 | 5 | 11 |
| other | 1 | 2 | 3 |
| Time from diagnosis of IA to surgery | |||
| Median (days) | 27 | 20 | 26 |
| range | (16–218) | (0–81) | (0–218) |
Group A comprises patients given caspofungin-based combination therapy starting within 7 days from diagnosis of IA; Group B consists of patients given caspofungin-based combination therapy starting after 7 days from diagnosis of IA.
IS, immunosuppressive drugs; IFI, invasive fungal infection; CNS, central nervous system; URA, upper respiratory airways; *with or without other IS drugs; CSA, cyclosporine-A, FK 506, tacrolimus.